Migraine Connect
  • Saved

EVALUATION OF INFLAMMATION PARAMETERS IN COMPLETE BLOOD COUNT IN PATIENTS DIAGNOSED WITH VESTIBULAR MIGRAINE

Source : https://www.kbb-forum.net/journal/text.php?&lang=en&id=537

Although various studies investigated the role of inflammation in migraine's pathophysiology, the importance of inflammation in VM has been studied in a very few reports [ 1, 6, 9, 20-...

  • Saved

Long-Term Efficacy and Safety of Erenumab

Long-Term Efficacy and Safety of Erenumab

Source : https://n.neurology.org/content/early/2021/04/28/WNL.0000000000012029.abstract

Objective To report the efficacy and safety of erenumab among episodic migraine (EM) patients who were unsuccessful on 2-4 preventive treatments observed at week 64 of Open-Label Extension Phase (OLEP)...

  • Saved

Recent refractory migraine patient
resistant to tryptans had great success with aimivog
She is able not to miss out on daily
activities

  • Saved

Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments - Heiko Pohl, Silvia Benemei, David Garcia-Azorin, Joanna Dixon, Elizabeth Huzzey, Michel D Ferrari, 2021

Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments - Heiko Pohl, Silvia Benemei, David Garcia-Azorin, Joanna Dixon, Elizabeth Huzzey, Michel D Ferrari, 2021

Source : https://doi.org/10.1177/03331024211006048

We propose a new outcome measure to assess the efficacy of migraine treatments translating the approach of the Global Burden of Disease studies from a societal to an individual level:...

  • Saved

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-021-01238-2

Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to...